Val-Cit-PAB-MMAE is primarily used in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. The compound serves as a linker-payload, connecting a monoclonal antibody to the cytotoxic agent MMAE (monomethyl auristatin E). The antibody specifically targets cancer cells, delivering the potent drug directly to the tumor while minimizing damage to healthy tissues. This approach enhances the efficacy of the treatment and reduces systemic toxicity. Val-Cit-PAB-MMAE is particularly utilized in therapies for various cancers, including lymphoma, breast cancer, and solid tumors, showcasing its role in advancing precision medicine.